Abstract:RRP is caused by HPV infection of the aerodigestive tract that significantly impacts quality‐of‐life including the ability to communicate and breathe. This study aims to determine whether rationale exists for combination therapeutic approaches using VEGF inhibitors and/or immune checkpoint blockade. Our analysis shows that RRP tissue shows elevated levels of multiple immune check point targets and VEGFR3, with varied patterns unique to each papilloma patient. Some of these immune checkpoint markers already have novel immunotherapies available or in development, providing molecular rationale to offer these systemic treatments to selected patients affected by RRP alongside VEGF inhibitors. Objectives Recurrent respiratory papillomatosis (RRP) is caused by human papilloma virus (HPV) infection of the aerodigestive tract that significantly impacts quality‐of‐life including the ability to communicate and breathe. Treatment was traditionally limited to serial ablative procedures in the O.R. with possible local adjuvant therapy, but new systemic therapies, such as Vascular endothelial growth factor (VEGF) inhibitors, are showing significant promise. This study aims to determine whether rationale exists for combination therapeutic approaches using VEGF inhibitors and/or immune checkpoint blockade. Methods Using fresh specimens from the O.R., we performed flow cytometry on papilloma, normal adjacent tissue, and blood. Papilloma and surrounding tissue were examined for expression of PD‐L1, PD‐L2, Galectin‐9, VEGFR2, and VEGFR3. CD8+ and CD4+ T cells were assayed for expression of PD‐1, TIGIT, LAG3, and TIM3. Results Our data shows that papilloma tissue exhibits significantly higher levels of PD‐L1 and PD‐L2 compared to adjacent tissue. Elevated levels of the VEGF receptor VEGFR3 were also observed in papilloma tissue. When examining T cells within the papilloma, elevated PD‐1 and TIGIT expression was observed on CD8+ T cells, while levels of PD‐1, TIGIT, and TIM3 were elevated on CD4+ T cells compared to PBMCs. Heterogenous marker expression was observed between individuals. Conclusions Our analysis shows that RRP tissue shows elevated levels of multiple immune check point targets and VEGFR3, with varied patterns unique to each papilloma patient. Some of these immune checkpoint markers already have novel immunotherapies available or in development, providing molecular rationale to offer these systemic treatments to selected patients affected by RRP alongside VEGF inhibitors. Laryngoscope, 2024

Recurrent respiratory papillomatosis: Immunological mechanisms involved in recurrence

Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis

VEGF as a Key Actor in Recurrent Respiratory Papillomatosis: A Narrative Review

Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes

Adjuvant Intralesional Bevacizumab in Pediatric and Adult Populations With Recurrent Respiratory Papillomatosis: A Systematic Review

HPV Vaccines for Treatment and Prevention of Recurrent Respiratory Papillomatosis

Current Practice, Safety and Efficacy of Interventions for Recurrent Respiratory Papillomatosis: Evidence From a UK Registry

Factors Associated with Recurrence and Therapeutic Strategies for Sinonasal Rosai–dorfman Disease

Systemic and local changes in the immunological status of patients with laryngeal papillomatosis

Quantification and Functional Studies of Neutrophilic Cells Identifies Distinct Papilloma Phenotypes

[Advances in the use of bevacizumab for the treatment of respiratory papilloma]

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis

Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review

Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution's Experience

The Preliminary Study on Mechanism of Immunological Evasion in Recurrent Respiratory Papillomatosis

[Primary study on glycan structure in pathopoiesis mechanism of recurrent respiratory papillomatosis].

Histological Severity Risk Factors Identification in Juvenile-Onset Recurrent Respiratory Papillomatosis: How Immunohistochemistry and AI Algorithms Can Help?

Intralesional Cidofovir: A Systematic Review of Administration Protocols and Long-term Recurrence Rates in Adult and Juvenile Recurrent Respiratory Papillomatosis

Risk Factors of Juvenile Onset Recurrent Respiratory Papillomatosis in the Lower Respiratory Tract

Clinical evaluation of pediatric patients with recurrent respiratory papillomatosis.

Effectiveness of combined approach to recurrent respiratory papillomatosis (RRP)